Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Kyverna Therapeutics, Inc.

News headline image
Kyverna Therapeutics Names Greg Martini as Chief Financial Officer
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
Tickers KYTX
News headline image
Kyverna Therapeutics to Present at Upcoming Investor Conferences
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
Tickers KYTX
News headline image
Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
Tickers KYTX
News headline image
Kyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
Tickers KYTX
News headline image
Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
Tickers KYTX
News headline image
Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
Tickers KYTX
News headline image
Kyverna Therapeutics to Host Conference Call on New Data Across Neuroimmunology Franchise at AAN 2026
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
Tickers KYTX
News headline image
Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
Tickers KYTX
News headline image
Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
Tickers KYTX
News headline image
Kyverna Therapeutics to Participate in Upcoming March Investor Conferences
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
Tickers KYTX
News headline image
Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
Tickers KYTX
News headline image
Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
Tickers KYTX
News headline image
Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
Tickers KYTX
News headline image
Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
Tickers KYTX
News headline image
Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
Tickers KYTX
News headline image
Kyverna Therapeutics Announces Proposed Public Offering of Common Stock
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
Tickers KYTX
News headline image
Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
Tickers KYTX
News headline image
Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
Tickers KYTX
News headline image
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
Tickers KYTX
News headline image
Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
Tickers KYTX
News headline image
Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
Tickers KYTX
News headline image
Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
Tickers KYTX
News headline image
Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
Tickers KYTX
News headline image
Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
Tickers KYTX
News headline image
Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
Tickers KYTX
News headline image
Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
Tickers KYTX
News headline image
Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
Tickers KYTX
News headline image
Kyverna Therapeutics to Present at Upcoming Investor Conferences in September
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
Tickers KYTX
News headline image
Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
Tickers KYTX
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.